Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mary-Kate Malecek
Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated With Dose-Adjusted EPOCH Plus Rituximab
American Journal of Hematology
Hematology
Repurposing Metformin for Cancer Treatment: Current Clinical Studies
Oncotarget
Oncology
Related publications
Correction To: White Matter Changes in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate With or Without Rituximab
Journal of Neuro-Oncology
Cancer Research
Oncology
Neurology
Treatment of Central Nervous System Lymphoma in Rats With Intraventricular Rituximab and Serum
International Journal of Hematology
Hematology
Factors Associated With Risk of Central Nervous System Relapse in Patients With Non-Core Binding Factor Acute Myeloid Leukemia
American Journal of Hematology
Hematology
Effect of Intravitreous Rituximab Injections in Patients With Recurrent Ocular Lesions Associated With Central Nervous System Lymphoma
Archives of Ophthalmology
Advances in Risk Assessment and Prophylaxis for Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
Haematologica
Hematology
A Case of Primary Cardiac Lymphoma Showing Isolated Central Nervous System Relapse
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Central Nervous System Relapse in Adolescents and Young Adults With Acute Lymphoblastic Lymphoma Treated With Total Body Irradiation and Hematopoietic Stem Cell Transplantation
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated With Dose-Adjusted EPOCH
Cancer Research and Treatment
Cancer Research
Oncology
Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated With Rituximab Plus Infusional EPOCH (AMC-034 Trial)
Clinical Cancer Research
Cancer Research
Oncology
